glp-1 receptor agonist antipsychotic weight gain study The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials GLP-1s Like Ozempic May Be
Description
10.1038/s41598-021-97967-0 Summary Keywords heart failure, GLP-1, glucagon-like peptide-1, clinical trials, cardiovascular disease, cardiovascular outcome studies, diabetes, obesity Citation Kreiner FF, Hovingh GKK and von Scholten BJ (2022) The potential of glucagon-like peptide-1 receptor agonists in heart failure
Weight-Loss Drug Frenzy Cements Novo Nordisk as Europes Most Valuable Company
The weekly doses were administered at 5 mg, 10 mg, 15 mg, 20 mg, or 40 mg for 46 weeks, whereas the biweekly doses were given at 20 mg, 40 mg, and 60 mg for 8 weeks
Curr Opin Behav Sci
Kushner, New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics, Annual Review of Medicine 2023
Rare cases of Stevens-Johnsons syndrome have been reported with sitagliptin
